Dublin, May 07, 2025 (GLOBE NEWSWIRE) -- The "High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
The global high content screening market is anticipated to reach USD 2.19 billion in 2030 from USD 1.52 billion in 2025, with a significant CAGR of 7.5%
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the high content screening and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The market is growing at a significant CAGR owing to the innovations in high-resolution imaging, automation, and artificial intelligence (AI)-powered data analysis, which have significantly enhanced the efficiency and accuracy of HCS workflows. Advanced instruments equipped with high-speed fluorescence microscopy, confocal imaging, and real-time live-cell analysis enable deeper cellular insights, making them essential for drug discovery, toxicity screening, and disease research.
Instruments dominated the products & service segment
Based on product & service, the high content screening market is divided into instruments, consumables & accessories, software, and services. The instrument segment is further divided into high content imaging platforms, cell detection and analysis systems, and cell imaging systems.
The rising demand for high-throughput screening and multiplexed assays in pharmaceutical and biotechnology research has accelerated the adoption of next-generation HCS systems. As research institutions and commercial laboratories seek to improve productivity and efficiency, the demand for cutting-edge HCS instruments is expected to drive significant market growth.
Drug discovery & development application segment is anticipated to grow at a great pace
The application segment is divided into drug discovery & development applications, toxicology, and basic research. The drug discovery & development application segment is further divided into primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications.
The drug discovery & development dominated the market owing to the integration of artificial intelligence and automation in drug discovery workflows further enhances the efficiency of HCS, reducing time and costs associated with preclinical research. Furthermore, regulatory bodies emphasize early toxicity assessment, making HCS a preferred choice for evaluating drug safety before clinical trials. These factors collectively contribute to the dominant market share of drug discovery and development applications in the HCS market.
Pharmaceutical & Biotechnology Companies dominated the segment
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. Pharmaceutical & biotechnology companies dominated the segment in 2024. The high share of pharmaceutical and biotechnology companies in the high content screening (HCS) market is primarily driven by their extensive use of HCS technologies in drug discovery and development. These companies rely on HCS for high-throughput screening, lead optimization, and toxicity assessment to accelerate the drug development process while ensuring safety and efficacy.
North America: the largest share of the high content screening market
North America dominated the high content screening market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of leading academic & research institutions, and significant investment in biotechnology. The country's focus on innovative medical research, personalized healthcare, and precision medicine further boosts its leadership in the market. European high content screening market is experiencing steady growth, supported by increasing research and development activities, especially in countries like Germany, the UK, and France.
Key Benefits of Buying the Report:
- Analysis of key drivers (Advancements in Imaging Technologies, Increased R&D projects, Adoption of High Throughput Screening, implementing organoid models in HCS), restraints (High Equipment and Reagents Costs, Complexity of Data Analysis), opportunities (Integration of AI and ML, Expansion into new applications) and Challenges (Lack of Standardized Protocol) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on upcoming technologies in high content screening, research and development activities, and new product launches in the high content screening market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the high content screening market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product & service offerings of leading players Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Merck KGaA (Germany), and Thermo Fisher Scientific, Inc. (US), among others.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 358 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value (USD) in 2025 | $1.52 Billion |
| Forecasted Market Value (USD) by 2030 | $2.19 Billion |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
Companies Featured
- Danaher Corporation
- Revvity
- Bd
- Thermo Fisher Scientific Inc.
- Agilent Technologies
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Nikon Instruments Inc.
- Carl Zeiss AG
- Sartorius AG
- Yokogawa Electric Corporation
- Tecan Trading AG
- Corning Incorporated
- Charles River Laboratories
- Evident
- Promega Corporation
- Creative Biolabsysmex Corporation
- Enzo Life Sciences
- Stratedigm Corporation
- Akoya Biosciences
- Sphere Fluidics
- Creative Biostructure
- Creative Bioarray
- Cell Signalling Technology
- Standard Biotools
- Araceli Biosciences
For more information about this report visit https://www.researchandmarkets.com/r/axb297
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
